Drug intelligence / Profile preview

10-valent pneumococcal conjugate vaccine

Development stage
Phase 4
Lead developer
GSK
Modality
Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

The 10-valent pneumococcal conjugate vaccine (PCV10) is a biologic vaccine designed to protect against infections caused by ten serotypes of the bacterium *Streptococcus pneumoniae*. It contains purified capsular polysaccharides from these serotypes, each individually conjugated to a carrier protein (often non-toxic diphtheria toxin), which enhances the immune response compared to unconjugated polysaccharide vaccines. The primary mechanism of action is immunostimulation, leading to opsonophagocytic killing of *S. pneumoniae* and subsequent protection against diseases such as invasive pneumococcal disease, otitis media, and pneumonia. PCV10 was developed by GlaxoSmithKline and is marketed under brand names including Synflorix and Streptorix[5][6][8]. It is administered intramuscularly and recommended for routine immunization in infants and young children.

Brand names
SynflorixStreptorix
Other names
Pneumococcal vaccine conjugate 10-valentPneumococcal 10-valent vaccine conjugatePneumococcal10-valent vaccine conjugatePneumococcal-10-valent vaccine conjugate
02

Targets

CPS (Streptococcus pneumoniae capsular polysaccharide)

Beyond the preview

Go deeper on 10-valent pneumococcal conjugate vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 10-valent pneumococcal conjugate vaccine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call